Company intelligence
Pharvaris
Pioneering science for patient choice
Pharmaceutical Manufacturing
Zug, CH
163 employees
Founded 2015
4 public signals
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists for bradykinin mediated diseases. Harnessing established science, the company aims to deliver oral bradykinin B2 receptor antagonists to help address unmet needs and improve standard of care. Our legacy, scientific expertise, and values drive our passion as we aspire to provide choice to people living with bradykinin-mediated diseases.
Verified activity
Signals from Pharvaris
4 published signals
Research & Knowledge
Pharvaris announced statistically significant and clinically meaningful topline results from the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release (XR) tablet for the prevention of hereditary angioedema attacks.
Reported by Pharvaris
People
Pharvaris is hiring a new Pharvarian to join the Quality Assurance GMP team reporting to Sascha Nydegger, Senior Director, QA GMP Lead, (Swiss RP).
Reported by Pharvaris
Presence & Recognition
Pharvaris shared translational, nonclinical, and clinical data on its investigational oral bradykinin B2 receptor antagonist during the Bradykinin Symposium 2026.
Reported by Pharvaris
Presence & Recognition
Pharvaris participated in an interactive gathering with Anne Marie Dering and Michael Altorfer from the Swiss Biotech Association.
Reported by Stefan Abele